Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mitochondrial bioenergetics and cardiolipin remodeling abnormalities in mitochondrial trifunctional protein deficiency
Eduardo Vieira Neto, Meicheng Wang, Austin J. Szuminsky, Lethicia Ferraro, Erik Koppes, Yudong Wang, Clinton Van’t Land, Al-Walid Mohsen, Geancarlo Zanatta, Areeg H. El-Gharbawy, Tamil S. Anthonymuthu, Yulia Y. Tyurina, Vladimir A. Tyurin, Valerian Kagan, Hülya Bayır, Jerry Vockley
Eduardo Vieira Neto, Meicheng Wang, Austin J. Szuminsky, Lethicia Ferraro, Erik Koppes, Yudong Wang, Clinton Van’t Land, Al-Walid Mohsen, Geancarlo Zanatta, Areeg H. El-Gharbawy, Tamil S. Anthonymuthu, Yulia Y. Tyurina, Vladimir A. Tyurin, Valerian Kagan, Hülya Bayır, Jerry Vockley
View: Text | PDF
Research Article Genetics Metabolism

Mitochondrial bioenergetics and cardiolipin remodeling abnormalities in mitochondrial trifunctional protein deficiency

  • Text
  • PDF
Abstract

Mitochondrial trifunctional protein (TFP) deficiency is an inherited metabolic disorder leading to a block in long-chain fatty acid β-oxidation. Mutations in HADHA and HADHB, which encode the TFP α and β subunits, respectively, usually result in combined TFP deficiency. A single common mutation, HADHA c.1528G>C (p.E510Q), leads to isolated 3-hydroxyacyl-CoA dehydrogenase deficiency. TFP also catalyzes a step in the remodeling of cardiolipin (CL), a phospholipid critical to mitochondrial membrane stability and function. We explored the effect of mutations in TFP subunits on CL and other phospholipid content and composition and the consequences of these changes on mitochondrial bioenergetics in patient-derived fibroblasts. Abnormalities in these parameters varied extensively among different fibroblasts, and some cells were able to maintain basal oxygen consumption rates similar to controls. Although CL reduction was universally identified, a simultaneous increase in monolysocardiolipins was discrepant among cells. A similar profile was seen in liver mitochondria isolates from a TFP-deficient mouse model. Response to new potential drugs targeting CL metabolism might be dependent on patient genotype.

Authors

Eduardo Vieira Neto, Meicheng Wang, Austin J. Szuminsky, Lethicia Ferraro, Erik Koppes, Yudong Wang, Clinton Van’t Land, Al-Walid Mohsen, Geancarlo Zanatta, Areeg H. El-Gharbawy, Tamil S. Anthonymuthu, Yulia Y. Tyurina, Vladimir A. Tyurin, Valerian Kagan, Hülya Bayır, Jerry Vockley

×

Figure 6

Functional assays of TFP/LCHAD-deficient fibroblasts.

Options: View larger image (or click on image) Download as PowerPoint
Functional assays of TFP/LCHAD-deficient fibroblasts.
Scatterplots with ...
Scatterplots with bars show means with SD. (A) Fatty acid oxidation (FAO) flux. Cells were grown at 37°C for 24 hours in media containing glucose and then incubated in glucose-free media containing [9,10 3H]-oleate and l-carnitine. FAO flux was measured by monitoring the release of 3H2O from [9,10 3H]-oleate. The release of 3H2O was significantly decreased in all patient fibroblasts. Data from 7 assays with 6 and 15 biological repeats of the mutant fibroblasts and control fibroblasts, respectively. Statistical test: ordinary 1-way ANOVA followed by Dunnett’s multiple comparisons test. (B) Electrospray ionization–MS/MS (ESI-MS/MS) acylcarnitine profile of fibroblast cell line FB854, compound heterozygous for 2 HADHB gene mutations: missense mutations c.1165A>G (p.N389D) and c.1289T>C (p.F430S). cps, counts per second. (C) ESI-MS/MS acylcarnitine profile of fibroblast cell line FB822, homozygous for the common LCHAD mutation, p.E510Q. Higher levels of C16-OH were observed. (D) Levels of key acylcarnitines in culture media after 72 hours’ overload with unlabeled palmitic acid. Data from 3 to 6 biological repeats of acylcarnitine profiles after 2 distinct challenges with unlabeled palmitic acid. Statistical test: ordinary 1-way ANOVA followed by Dunnett’s multiple comparisons test. P values: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, compared with FB826, a control cell line from a 40-year-old woman.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts